Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | NAMPT | P43490 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7956246 | 0.88 | SMN1; SMN2 (0.44) | CYP19A1NAMPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL7958300 | 0.86 | KMT2A (0.53) | LMNASMN1; SMN2GAAL3MBTL1KMT2A | |
| SCHEMBL7956458 | 0.86 | POLB (0.51) | CYP19A1NAMPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL7956244 | 0.84 | CYP19A1 (0.65) | CYP19A1NAMPTLMNASMN1; SMN2HRH1 | |
| SCHEMBL7958986 | 0.83 | HTR7 (0.51) | SMN1; SMN2L3MBTL1THRBKMT2AMEN1 | |
| SCHEMBL7947310 | 0.82 | MCOLN3 (0.50) | NAMPTGAAL3MBTL1HSD11B1 | |
| SCHEMBL7956809 | 0.79 | SETDB1 (0.53) | SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7956445 | 0.78 | NAMPT (0.52) | NAMPT | |
| SCHEMBL7956464 | 0.76 | SMN1; SMN2 (0.47) | CYP19A1LMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL7947312 | 0.74 | SLC22A12 (0.50) | LMNASMN1; SMN2GAAL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6313127-B1 | FOR THERAPY OF HYPERCHOLESTEROLEMIA OR ATHEROSCLEROSIS | ZENECA LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0880501-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997028128-A1 | HETEROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICAL AGENTS | ZENECA LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |